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Section 2. Key Exclusion Criteria and Key Secondary Endpoints  
Key exclusion criteria were: prior treatment with lymphocyte-depleting or alkylating agents; 
hemoglobin <9.0 g/dL or hematocrit <30%, white blood cell count <3.0 × 109/L, absolute 
neutrophil count <1.2 × 109/L, or platelet count <100 × 109/L; estimated glomerular filtration 
rate <60 mL/min (abbreviated Modification of Diet in Renal Disease calculation); aspartate 
aminotransferase or alanine aminotransferase >1.5× the upper limit of normal; history of 
another autoimmune rheumatic disease except Sjögren’s syndrome; history of serious 
infection, including hepatitis B/C or human immunodeficiency virus; evidence of active, 
latent or inadequately treated Mycobacterium tuberculosis infection; history of 
lymphoproliferative disorder; history of malignancy except adequately treated non-metastatic 
basal/squamous cell cancer of the skin or cervical carcinoma in situ. 
Additional key secondary endpoints to those described in the article included (at all visits, 
unless stated otherwise): (i) the proportions of patients achieving ACR20/50/70 response 
(ACR70 response at Month 6 co-primary endpoint); (ii) change from baseline in physical 
function measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) 
(range 0–3: 0–1, mild to moderate physical difficulty; >1–2, moderate to severe disability; 
>2–3, severe to very severe disability);1,2 (iii) the proportion of patients achieving Disease 
Activity Score (DAS) <2.6 (DAS28-remission) and ≤3.2 (low disease activity) in 28 joints 
based on DAS28-4(ESR) (range 0–9.4)3 (a composite index of four weighted variables: 28 
tender joint-count [range 0–28]; 28 swollen joint-count [range 0–28]; (iv) the level of disease 
activity is interpreted as low [DAS28≤3.2], moderate [3.2<DAS28≤5.1] or high 
[DAS28>5.1]; as per these criteria, DAS28<2.6 corresponds to being in remission;4-6 (v) ESR 
[range 0–150]; Patient’s Global Assessment of Disease Activity on a visual analog scale 
[range 0–100]; (vi) Patient’s Assessment of Arthritis Pain on a visual analog scale [range 0–
6 
100], and; (vii) the Functional Assessment of Chronic Illness Therapy-Fatigue (13-item 
questionnaire; range 0–52; higher scores represent less fatigue)7 at Month 6. 
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Section 3. Statistical Analysis 
The full analysis set for efficacy and safety included all randomized patients who received ≥1 
dose of study medication and had a baseline and at least one post-baseline measurement.  
To control the type I error rate in the primary analyses, co-primary efficacy endpoints were 
assessed sequentially using a step-down approach where statistical significance could be 
claimed: 
• For tofacitinib 10 mg twice daily difference from methotrexate in progression in 
modified Total Sharp Score (mTSS), if P≤0.05. 
• For tofacitinib 5 mg twice daily difference from methotrexate in progression in 
mTSS, if P≤0.05 and tofacitinib 10 mg difference from methotrexate in progression in 
mTSS also had P≤0.05. 
• For tofacitinib 10 mg twice daily difference from methotrexate in rates of ACR70 
response, if P≤0.05 and tofacitinib 10 mg difference from methotrexate in progression 
in mTSS also had P≤0.05. 
• For tofacitinib 5 mg twice daily difference from methotrexate in rates of ACR70 
response, if P≤0.05 and tofacitinib 10 mg difference from methotrexate in rates of 
ACR70 also had P≤0.05, and tofacitinib 5 mg difference from methotrexate in 
progression in mTSS if P ≤0.05 (Fig. S1)  
No adjustment for multiple comparisons was applied to secondary endpoints; P≤0.05 was 
considered to indicate statistical significance. 
The primary analysis for the change in mTSS from baseline to Month 6 was conducted by an 
analysis of covariance model that included baseline mTSS, duration of rheumatoid arthritis 
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and geographic region as covariates. For the primary analysis of mTSS and its components 
(erosion score and JSN score), missing values due to patient withdrawal were linearly 
extrapolated based on the baseline value and the post-baseline value prior to withdrawal. For 
the analysis of ACR70 response rates and other binary endpoints, the normal approximation 
for the difference in binomial proportions was used to test the superiority of each dose of 
tofacitinib to methotrexate. Missing values due to a patient dropping from the study for any 
reason were handled by setting the value to non-responsive (non-responder imputation; also 
applied to secondary endpoints with binary variables). HAQ-DI was expressed as least 
squares mean change from baseline and analyzed using a mixed-effect longitudinal model 
that included fixed effects of treatment, visit and treatment-by-visit interaction and covariates 
of baseline HAQ-DI, duration of rheumatoid arthritis and geographic region; patients were a 
random effect. Remaining continuous endpoints also followed this analysis. Safety data were 
summarized descriptively, and as least squares means for selected variables.  
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Section 4. Summary Narratives for Confirmed (n=6) and Unconfirmed Malignancies (n=1) 
Confirmed 
1. A 65-year-old man in the tofacitinib 10 mg twice daily treatment group discontinued 
the study due to high-grade B-cell Burkitt-like lymphoma on Day 149. The investigator 
considered the event to be related to study medication. His last dose of study medication was 
on Day 171. A fine-needle biopsy of the neck showed B-cell non-Hodgkin lymphoma. 
Staining for Epstein-Barr virus (EBV)-positive cells was equivocal. On Day 185, the patient 
was given chemotherapy and transferred to the local hospital for palliative care. As of the cut-
off date for the 1-year analysis, no further information was available. The patient withdrew 
consent for further contact. 
2. A 61-year-old woman in the tofacitinib 10 mg twice daily group experienced a serious 
adverse event of colon cancer. Relevant medical history included abdominal pain at the start 
of the study. The patient discontinued study medication on Day 351. On Day 378, the onset 
date of event was reported, which corresponded to the date of the first computed tomography 
scan diagnosing the mass itself. Records did not show any treatment given for the colon 
cancer. Approximately 5 months later, the patient developed a cerebrovascular accident, 
pneumonia, nervous system disorder, and disseminated intravascular coagulation considered 
medically significant. The patient died in her sleep. No autopsy was performed. Per the 
investigator, these events were considered to be not related to study drug. 
3. A 65-year-old man in the tofacitinib 10 mg twice daily group had a prostate-specific 
antigen (PSA) level of 2.9 ng/mL several years prior to the study. The patient was 
randomized to treatment and PSA increased to 4.25 ng/mL after approximately 200 days of 
treatment. Following more than a year of study treatment, his PSA level was 5.99 ng/mL. A 
pathology report confirmed prostatic adenocarcinoma. Study drug was withdrawn shortly 
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thereafter. A month later, the patient was reported recovered from event after prostatic 
resection. The investigator considered the event to be not related to study drug, but likely to a 
pre-existing condition. 
4. A 63-year-old man in the tofacitinib 5 mg twice daily group developed leukocytosis at 
approximately 3 months, and proliferation of lymphoid tissue at approximately 6 months, 
after the data cut-off date. Study medication was discontinued at this time. A specific 
diagnosis of T-lymphoproliferative T-cell chronic lymphocytic leukemia – non-Hodgkin 
lymphoma was made 3 months later (9 months after the data cut-off date). Staining for EBV-
positive cells was reported as negative. Relevant medical history included splenectomy in 
2003 due to suspected Felty’s syndrome. The investigator considered the event to be 
unrelated to study drug. 
5  A 71-year-old women in the tofacitinib 5 mg twice daily group died 765 days after the 
first dose of study medication. The cause of death was reported as diffuse non-Hodgkin 
lymphoma. The patient’s previous medical history included cholelithiasis with 
cholecystectomy, ongoing cholestasis, ongoing varicose veins, ongoing osteochondrosis, 
urolithiasis and arterial hypertension. Concomitant medications included oral prednisolone, 
oral drotaverine hydrochloride, oral herbal (not otherwise specified) minerals and oral 
indapamide. Study medication was discontinued after Day 723. The patient died on Day 765, 
12 days after being urgently hospitalized with a preliminary diagnosis of degenerative 
vertebral disease: paraparesis of lower extremities, hemorrhagic cystitis. The investigator 
reported the cause of death as diffuse non-Hodgkin lymphoma and considered there was a 
reasonable possibility that the event was related to study drug. 
6. A 61-year-old woman in the methotrexate group reported diagnosis of cancer of 
stomach confirmed by gastroscopy at Day 412. The patient was receiving 20 mg 
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methotrexate/week at the time of the event. Study medication was discontinued after Day 
357. Following subtotal resection of stomach and lymph nodes, the patient was considered to 
have recovered with sequelae. The investigator considered there was a reasonable possibility 
that the event was related to study drug. 
Unconfirmed 
1. An adrenal adenoma with cellular atypia, which the local pathologist was unable to 
confirm as malignant or benign, was also reported in a 38-year-old male receiving tofacitinib 
5 mg twice daily. On Day 139, a computed tomography scan was performed, which was 
suggestive of suprarenal adenoma. The patient was admitted to hospital on Day 148 for 
adrenalectomy and cholecystectomy. A right adrenalectomy was performed on Day 150 to 
remove a right suprarenal adenoma; cholecystectomy was also performed on this date. The 
patient recovered from the event of adrenal adenoma on Day 150. The patient was withdrawn 
from the study on Day 174 in response to the events of osteonecrosis and adrenal adenoma.  
The last dose of tofacitinib tablets was administered on Day 126. The investigator considered 
there was not a reasonable possibility that the event was related to study drug. 
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Section 5. Summary Narratives for Deaths (n=4) 
1. A 61-year-old woman in the tofacitinib 10 mg twice daily group had a serious adverse 
event of colon cancer. The patient discontinued study medication on Day 351. On Day 378, 
the onset date of event was reported, which corresponded to the date of the first computed 
tomography scan diagnosing the mass itself. Records did not show any treatment given for 
the colon cancer. Approximately 5 months later, the patient developed cerebrovascular 
accident, pneumonia, nervous system disorder, and disseminated intravascular coagulation 
considered medically significant. The patient died in her sleep approximately 530 days after 
the first dose of study medication. No autopsy was performed. These events were considered 
to be not related to study drug by the investigator. 
2. A 53-year-old woman in the tofacitinib 5 mg twice daily group was found dead at home 
472 days after the first dose of study medication. The probable cause of the patient’s death 
was myocardial infarction. The investigator reported the event term as “Death – unknown 
causes.” No autopsy was performed. The patient had no prior medical history of any 
cardiovascular disease other than systemic arterial hypertension; after review of the 
information available, the external Cardiac Adjudication Review Committee determined this 
case as Sudden Cardiac Death. The patient’s father died at age 45 and sister at age 36, both 
from myocardial infarction. The investigator considered there was a reasonable possibility 
that the event of death was related to study drug. 
3. A 61-year-old-woman in the tofacitinib 5 mg twice daily group died 685 days after the 
first dose of study medication. Except for rheumatoid arthritis, the patient had not been 
treated for any other condition. Relevant medical history included that the patient was a 
heavy smoker and had undergone a lung X-ray examination at a rheumatology department 
that revealed a spheroidal shade at the top of right hilus, subsequently confirmed as 
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chondroma. The patient had no further lung problems. Relevant concomitant medications 
included oral ibuprofen and ongoing folic acid. The patient was reportedly without any 
difficulties on the date of death and autopsy findings included: atherosclerosis of coronary 
vessels and aorta grade II-III, chronic bronchitis, chronic pulmonary emphysema, post-partial 
resection of the right lung, chronic cor pulmonale, edema of the brain and edema of the lung. 
The investigator reported the cause of death as cardiac failure (Exacerbation of Chronic Heart 
Failure) considered to be not related to study drug. 
4. A 71-year-old women in the tofacitinib 5 mg twice daily group died 765 days after the 
first dose of study medication. The cause of death was reported as diffuse non-Hodgkin 
lymphoma. The patient’s previous medical history included cholelithiasis with 
cholecystectomy, ongoing cholestasis, ongoing varicose veins, ongoing osteochondrosis, 
urolithiasis and arterial hypertension. Concomitant medications included oral prednisolone, 
oral drotaverine hydrochloride, oral herbal (not otherwise specified) minerals and oral 
indapamide. Study medication was discontinued after Day 723. The patient died on Day 765, 
12 days after being urgently hospitalized with a preliminary diagnosis of degenerative 
vertebral disease: paraparesis of lower extremities, hemorrhagic cystitis. The investigator 
reported the cause of death as diffuse non-Hodgkin lymphoma and considered there was a 
reasonable possibility that the event was related to study drug. 
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Figure S1. The Step-Down Approach to Assigning Statistical Significance for the Co-
Primary Endpoints. 
 
Testing continued along an arrow until a Diamond was false. All testing stopped when testing along all arrows 
stopped. Figure shows tested steps, but significance of a test (denoted by each Box) was determined when 
P≤0.05, provided the Box itself was reached while stepping through the figure. 
ACR70, American College of Rheumatology (ACR)70 response: ≥70% improvement from baseline in both 
tender and swollen joint counts and ≥70% improvement in ≥3 of the five remaining ACR core set measures 
[pain, disability, CRP, patient and physician global assessments]), mTSS, modified total Sharp score 
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Figure S2. Patient Disposition. 
 
N, total number of patients; n, number of patients evaluable 
The proportion of patients who discontinued due to adverse events is tabulated from the patient disposition or 
summary pages for discontinuations. The number of patients might not be the same as those in the safety 
summary, which uses the adverse event pages.  
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Figure S3. Preventive Effect on Radiographic Progression: (A) Mean Change From Baseline 
in mTSS at Month 6 (Co-Primary Endpoint¥), (B) Mean Change From Baseline in mTSS, (C) 
Erosion Score, and (D) Joint Space Narrowing Score Over Time (LEP).  
A 
 
B 
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C 
 
D 
 
  
Number of Patients at Visit/Baseline (n/N) 
  
Month 
6  
Month 
12 
 
Month  
24 
Tofacitinib 5 mg twice daily 
 
348/373  347/373 
 
348/373 
Tofacitinib 10 mg twice daily 
 
372/396  373/396 
 
373/396 
Methotrexate 
 
167/186  171/186 
 
171/186 
Patient numbers relate to Figure S3 B, C, and D 
 
Values are least squares mean changes from baseline (baseline values are reported in Table 1)  
LEP, imputation using linear extrapolation; mTSS, van der Heijde modified total Sharp score; SE, standard error 
*P≤0.05; **P<0.001 versus methotrexate 
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Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
¥Co-primary endpoint (mean change from baseline in mTSS) at Month 6 was derived from the pre-specified 
Year 1 interim dataset; mean changes from baseline in mTSS and component scores over time were derived 
from the final Year 2 dataset 
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Figure S4. Preventive Effect on Radiographic Progression using a Longitudinal Linear 
Model as Sensitivity Analysis with no Imputation for Missing Data: (A) Mean Change From 
Baseline in mTSS at Month 6 (Co-Primary Endpoint¥), (B) Mean Change From Baseline in 
mTSS, (C) Erosion Score, and (D) Joint Space Narrowing Score Over Time.  
A 
 
B 
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C 
 
D 
 
  Number of Patients at Visit/Baseline (n/N)  
  Month  
6 
Month  
12 
 Month  
24 
 
Tofacitinib 5 mg twice daily  335/373 313/373  258/373  
Tofacitinib 10 mg twice daily  364/396 330/396  282/396  
Methotrexate  160/186 132/186  104/186  
Patient numbers relate to Figure S4 B,C and D  
The total number of patients contributing some data to the longitudinal model were 335 (tofacitinib 5 mg twice 
daily), 365 (tofacitinib 10 mg twice daily), and 164 (methotrexate). 
 
Values are least squares mean changes from baseline 
mTSS, van der Heijde modified total Sharp score; SE, standard error 
*P≤0.05; **P<0.001 versus methotrexate 
 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
¥Co-primary endpoint (mean change from baseline in mTSS) at Month 6 was derived from the pre-specified 
Year 1 interim dataset; mean changes from baseline in mTSS and component scores over time were derived 
from the final Year 2 dataset 
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Figure S5. Proportion of Patients with no Structural Progression (≤0.5 Unit Increase From 
Baseline in mTSS) at Months 6, 12, and 24. 
 
 
mTSS, van der Heijde modified total Sharp score; SE, standard error 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
*P≤0.05; **P<0.001 versus methotrexate 
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Figure S6. Cumulative Probability Plots for Change from Baseline in mTSS Showing the 
Full Percentile (0-100%), and the Lower (0-20%) and Upper (80-100%) Percentiles, at (A) 
Month 6, (B) Month 12, and (C) Month 24. 
A  
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B 
 
 
 
 
 
24 
C  
 
  
mTSS, van der Heijde modified total Sharp score 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
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Figure S7. (A) ACR70 at Month 6 (Co-Primary Endpoint¥), (B) ACR20, (C) ACR50, and (D) 
ACR70 Response Over Time (NRI, FAS). 
A 
 
B 
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C 
 
D) 
 
ACR, American College of Rheumatology; FAS, full analysis set; NRI, non-responder imputation; SE, standard 
error 
*P≤0.05; **P<0.001 versus methotrexate 
 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
¥Co-primary endpoint (ACR70 at Month 6) was derived from the pre-specified Year 1 interim dataset; ACR70 
responses over time were derived from the final Year 2 dataset. 
27 
Figure S8. Proportion of Patients Achieving DAS28-Defined (A) Remission (DAS28-4(ESR) 
<2.6), and (B) Low Disease Activity (DAS28-4(ESR) ≤3.2) (FAS, NRI) over 24 Months. 
A 
 
B 
 
*P≤0.05; **P<0.001 versus methotrexate 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; FAS, full analysis set; NRI, non-responder 
imputation; SE, standard error 
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Table S1. Further Details on Baseline Demographics and Disease Characteristics.* 
 Tofacitinib 5 mg 
Twice Daily 
(N=373) 
Tofacitinib 10 mg 
Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Female sex, no. (%) 286 (76.7) 327 (82.4) 145 (78.0) 
White ethnic group, no. (%) 239 (64.1) 266 (67.0) 127 (68.3) 
Age, mean years 50.3 49.3 48.8 
Duration of rheumatoid arthritis 
    Mean, years 
    Median, years 
    <2 years, %  
    <6 months, % 
 
2.9 
0.8 
67.0 
39.7 
 
3.4 
0.8 
63.7 
40.6 
 
2.7 
0.7 
66.1 
39.2 
Tender joints, mean no. 25.7 25.1 25.4 
Swollen joints, mean no. 16.3 15.6 16.8 
HAQ-DI, mean† 1.54 1.50 1.52 
mTSS, mean‡ 
mTSS, median‡ 
19.1 
3.5 
17.9 
3.0 
16.1 
3.5 
Erosion score, mean¥ 9.1 9.1  8.4  
Joint space narrowing score, mean§ 10.0 8.8  7.7  
DAS28-4(ESR), mean¢ 6.62 6.54 6.60 
DAS28-4(ESR) score of >5.1, % 94.4 93.7 93.0 
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 Tofacitinib 5 mg 
Twice Daily 
(N=373) 
Tofacitinib 10 mg 
Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
ESR, mm/h 55.6 53.4 56.0 
CRP, mg/L 22.7 20.3 25.9 
Positive for RF, % 82.3 81.6 84.4 
Positive for anti-CCP antibodies, % 85.0 81.1 86.6 
Prior treatment, nonbiologic 
disease modifying drug other than 
methotrexate, % 
37.0 39.8 41.4 
   Leflunomide, n  22  25  13  
   Sulfasalazine, n  53  47  23  
   Anti-malarial drugs, n 89 116 57 
   Gold salt preparations, n  1  4  2  
 
*There were no statistically significant differences between treatment group demographics and disease 
characteristics at baseline (subgroups under the ‘Prior treatment, nonbiologic disease-modifying drug other than 
methotrexate’ category were not statistically tested due to small patient numbers) 
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte 
sedimentation rate; HAQ-DI, Health Assessment Questionnaire - Disability Index; mTSS, modified total Sharp 
Score; RF, rheumatoid factor 
†Scores of 0 to 1 generally represent mild to moderate physical difficulty, 1 to 2 moderate to severe disability, 
and 2 to 3 severe to very severe disability; ‡Range 0–448, higher scores indicate greater structural damage; 
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¥Range 0–280, higher scores indicate greater erosive changes in the joints; §Range 0–168, higher scores indicate 
greater narrowing between joints; ¢DAS28-4, range 0–9.4, higher scores indicate greater disease activity 
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Table S2. Further Details on Co-primary¶ and Secondary Endpoints§ at Months 6, 12, and 24. 
 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg  
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
ACR20†, % (SE) 71.3** 
(2.35) 
76.1** 
(2.14) 
50.5 
(3.68) 
67.8** 
(2.43) 
71.6** 
(2.27) 
51.1  
(3.68) 
64.2** 
(2.49) 
64.2**  
(2.41) 
42.4 
(3.64) 
ACR50†, % (SE) 46.6** 
(2.59) 
56.4** 
(2.49) 
26.6  
(3.25) 
49.9** 
(2.60) 
55.6** 
(2.50) 
33.7 
 (3.48) 
49.3** 
(2.60) 
49.2** 
(2.51) 
28.3 
(3.31) 
ACR70†¥, % (SE) 25.5** 
(2.26) 
37.7** 
(2.44) 
12.0  
(2.39) 
28.7** 
(2.35) 
38.1** 
(2.44) 
15.2  
(2.64) 
34.4** 
(2.47) 
37.6** 
(2.43) 
15.2  
(2.64) 
DAS28-4(ESR) <2.6†, % (SE) 14.6* 
(1.91) 
21.8** 
(2.13) 
7.60  
(2.02) 
18.7* 
(2.10) 
23.4** 
(2.19) 
11.70 
(2.45) 
20.8** 
(2.19) 
22.3** 
(2.15) 
9.94 
(2.28) 
DAS28-4(ESR) ≤3.2†, % (SE) 27.8** 
(2.42) 
38.2** 
(2.51) 
14.0 
 (2.65) 
33.3** 
(2.54) 
41.1** 
(2.55) 
18.7 
(2.98) 
34.8** 
(2.57) 
36.0** 
(2.48) 
15.8 
(2.78) 
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg  
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Mean change (SE) from baseline in 
DAS28-4(ESR)∫# 
-2.47** 
(0.07) 
-2.88** 
(0.07) 
-1.87 
 (0.10) 
-2.78** 
(0.07) 
-3.05** 
(0.07) 
-2.20  
(0.11) 
-2.99** 
(0.08) 
-3.16** 
(0.07) 
-2.40 
(0.12) 
EULAR response (Good or Moderate)†, % 
(SE) 
79.0** 
(2.20) 
84.1** 
(1.89) 
60.82  
(3.73) 
76.6** 
(2.28) 
79.6** 
(2.09) 
59.7  
(3.75) 
68.7** 
(2.5) 
69.6** 
(2.38) 
49.12 
(3.82) 
Mean change (SE) from baseline in 
HAQ-DI∫# 
-0.83** 
(0.03) 
-0.94** 
(0.03) 
-0.58 
 (0.04) 
-0.87** 
(0.03) 
-0.98** 
(0.03) 
-0.68  
(0.04) 
-0.90** 
(0.03) 
-1.01** 
(0.03) 
-0.70 
(0.05) 
LS mean change (SE) from baseline in 
mTSS‡¥# 
0.18* 
(0.12) 
0.04** 
(0.11) 
0.84 
(0.16) 
0.36** 
(0.14) 
0.16** 
(0.14) 
1.18 
 (0.20) 
0.55**  
(0.25) 
0.28** 
(0.24) 
2.08 
(0.34) 
LS mean change (SE) from baseline in 
erosion score‡ 
0.14* 
(0.04) 
0.10** 
(0.04) 
0.35 
(0.06) 
0.13** 
(0.07) 
0.12** 
(0.06) 
0.58  
(0.09) 
0.16** 
(0.11) 
0.16** 
(0.10) 
0.98 
(0.15) 
LS mean change (SE) from baseline in 
joint space narrowing score‡ 
0.06* 
(0.06) 
0.05* 
(0.06) 
0.29 
(0.09) 
0.23* 
(0.10) 
0.05* 
(0.10) 
0.60 
(0.14) 
0.39* 
(0.18) 
0.12** 
(0.17) 
1.10 
(0.25) 
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg  
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Patients with no radiographic progression 
(mTSS change from baseline ≤0.5)‡, % 
(SE) 
87.1** 
(1.79) 
89.3** 
(1.60) 
73.7  
(3.40) 
82.4* 
(2.04) 
87.7** 
(1.70) 
69.0 
(3.53) 
79.9** 
(2.14) 
83.7** 
(1.91) 
64.9 
(3.64) 
†Non-responder imputation; ‡Linear extrapolation; ∫Mixed-effect longitudinal model; #Least squares means from analysis of covariance or mixed-effect longitudinal 
model; ¶Statistical significance at Month 6 (co-primary endpoint) was determined using the step-down approach; ¥All data in this table were derived from the Year 2 
dataset except the co-primary endpoints (ACR70 and mean change from baseline in mTSS) at Month 6 which were derived from the pre-specified Year 1 dataset; §No 
accounting for multiple comparisons; P≤0.05 was considered to indicate statistical significance 
ACR, American College of Rheumatology; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ-
DI, Health Assessment Questionnaire - Disability Index; LS, least squares; mTSS, modified total Sharp Score; SE, standard error 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week  
*P≤0.05; **P<0.001 versus methotrexate 
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Table S3. ACR Core Components at Month 6.  
 Tender 
/ Painful Joint 
Count 
Swollen Joint 
Count 
Patient’s 
Assessment of 
Pain 
Patient’s Global 
Assessment of 
Disease Activity 
Physician’s Global 
Assessment of 
Disease Activity 
Health 
Assessment 
Questionnaire 
– Disability 
Index 
C-Reactive 
Protein, mg/L 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
Tofacitinib 5 mg twice daily 
Baseline 373 25.7  
(0.7) 
373 16.3  
(0.5) 
373 59.1  
(1.2) 
373 60.2  
(1.3) 
369 62.0  
(0.9) 
373 1.54 
(0.03) 
373 22.7 
(1.4) 
Month 6 340 8.7 
(0.6) 
340 4.7  
(0.4) 
340 27.1  
(1.2) 
340 28.4  
(1.2) 
339 22.2 
(0.9) 
340 0.69 
(0.03) 
339 5.2 
(0.6) 
Mean change from 
baseline at Month 6# 
340 -16.0** 
(0.6) 
340 -10.9* 
(0.4) 
340 -31.9* 
(1.2) 
340 -31.7* 
(1.2) 
336 -39.0** 
(0.9) 
340 -0.83** 
(0.03) 
339 -17.0** 
(0.7) 
Tofacitinib 10 mg twice daily 
Baseline 397 25.1 
(0.7) 
397 15.6  
(0.4) 
397 61.4  
(1.2) 
397 60.9  
(1.1) 
394 60.5 
 (0.9) 
396 1.50  
(0.03) 
397 20.3  
(1.2) 
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 Tender 
/ Painful Joint 
Count 
Swollen Joint 
Count 
Patient’s 
Assessment of 
Pain 
Patient’s Global 
Assessment of 
Disease Activity 
Physician’s Global 
Assessment of 
Disease Activity 
Health 
Assessment 
Questionnaire 
– Disability 
Index 
C-Reactive 
Protein, mg/L 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
N Mean 
(SE) 
Month 6 367 6.6 
(0.5) 
367 3.7 
(0.3) 
366 24.2 
(1.1) 
366 24.8  
(1.1) 
366 18.3  
(0.8) 
366 0.57  
(0.03) 
366 3.1  
(0.3) 
Mean change from 
baseline at Month 6# 
367 -18.1** 
(0.5) 
367 -12.0** 
 (0.4) 
366 -35.4** 
(1.2) 
366 -35.1** 
(1.2) 
363 -42.5** 
(0.8) 
365 -0.94** 
(0.03) 
366 -18.8** 
(0.7) 
Methotrexate 
Baseline 186 25.4  
(1.1) 
186 16.8  
(0.8) 
186 58.8  
(1.7) 
186 57.7  
(1.8) 
185 59.3  
(1.3) 
186 1.52  
(0.05) 
186 25.9 
(2.3) 
Month 6 158 12.0  
(1.1) 
158 6.3 
(0.6) 
158 30.9  
(1.8) 
158 32.1  
(1.7) 
158 27.3  
(1.3) 
158 0.92  
(0.05) 
158 12.2 
(1.5) 
Mean change from 
baseline at Month 6 
158 -12.4  
(0.8) 
158 -9.4 
 (0.5) 
158 -27.7 
(1.7) 
158 -27.0 
(1.7) 
157 -33.4 
 (1.3) 
158 -0.58  
(0.04) 
158 -9.7 
(1.0) 
#Mean changes from baseline were estimated from a longitudinal model using least-squares means and comparisons versus methotrexate were tested.  Values for baseline 
and Month 6 are simple means with no adjustment using any kind of model. 
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*P≤0.05; **P<0.001 versus methotrexate 
ACR, American College of Rheumatology; SE, standard error 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
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Table S4. All-Causality Treatment-Emergent Adverse Events Occurring in ≥2% of Patients in Any Treatment Group over 24 Months.  
Preferred Term Patients with Adverse Event, n (%) 
 Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Adverse events 1097 1435 561 
Anemia 15 (4.0) 12 (3.0) 7 (3.8) 
Abdominal pain 8 (2.1)† 16 (4.0)† 2 (1.1) 
Abdominal pain upper 12 (3.2) 13 (3.3) 5 (2.7) 
Constipation 7 (1.9) 10 (2.5) 7 (3.8)‡ 
Diarrhea 15 (4.0) 24 (6.0) 15 (8.1)‡ 
Dyspepsia 13 (3.5) 18 (4.5) 9 (4.8)‡ 
Gastritis 13 (3.5)† 9 (2.3) 4 (2.2) 
Gastroesophageal reflux disease 6 (1.6) 6 (1.5) 5 (2.7) 
Nausea 27 (7.2) 30 (7.6) 40 (21.5)‡ 
Vomiting 11 (2.9) 13 (3.3) 11 (5.9)‡ 
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Preferred Term Patients with Adverse Event, n (%) 
 Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Asthenia 1 (0.3) 7 (1.8) 5 (2.7) 
Fatigue 8 (2.1) 10 (2.5) 7 (3.8)‡ 
Edema peripheral 11 (2.9) 17 (4.3)† 5 (2.7) 
Pyrexia 5 (1.3) 3 (0.8) 6 (3.2) 
Bronchitis 20 (5.4)† 27 (6.8)† 4 (2.2) 
Cystitis 8 (2.1)† 3 (0.8) 1 (0.5) 
Gastroenteritis 11 (2.9) 15 (3.8) 7 (3.8) 
Herpes zoster 13 (3.5)† 18 (4.5)† 2 (1.1) 
Influenza 10 (2.7)† 11 (2.8)† 3 (1.6) 
Nasopharyngitis 28 (7.5) 39 (9.8)† 13 (7.0) 
Oral herpes 7 (1.9) 8 (2.0) 5 (2.7) 
Pharyngitis 9 (2.4) 12 (3.0) 4 (2.2) 
39 
Preferred Term Patients with Adverse Event, n (%) 
 Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Pneumonia 8 (2.1)† 4 (1.0) 1 (0.5) 
Respiratory tract infection viral 12 (3.2)† 6 (1.5) 4 (2.2) 
Sinusitis 9 (2.4) 9 (2.3) 5 (2.7) 
Upper respiratory tract infection 30 (8.0) 39 (9.1)† 15 (8.1) 
Urinary tract infection 17 (4.6) 26 (6.5)† 7 (3.8) 
Alanine aminotransferase increased 8 (2.1) 15 (3.8) 11(5.9)‡ 
Aspartate aminotransferase increased 3 (0.8) 11 (2.8) 7 (3.8)‡ 
Blood creatine phosphokinase increased 16 (4.3)† 36 (9.1)† 2 (1.1) 
Gamma-glutamyltransferase increased 8 (2.1)† 14 (3.5)† 2 (1.1) 
Hemoglobin decreased  5 (1.3) 3 (0.8) 4 (2.2) 
Weight increased 13 (3.5)† 17 (4.3)† 4 (2.2) 
Dyslipidemia 8 (2.1)† 10 (2.5)† 1 (0.5) 
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Preferred Term Patients with Adverse Event, n (%) 
 Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Hypercholesterolemia 9 (2.4)† 15 (3.8)† 1 (0.5) 
Arthralgia 8 (2.1) 17 (4.3) 8 (4.3)‡ 
Arthritis 8 (2.1) 5 (1.3) 4 (2.2) 
Back pain 19 (5.1)† 18 (4.5)† 4 (2.2) 
Osteoarthritis 5 (1.3) 9 (2.3)† 2 (1.1) 
Pain in extremity 9 (2.4) 7 (1.8) 3 (1.6) 
Rheumatoid arthritis flare 10 (2.7) 7 (1.8) 5 (2.7) 
Dizziness 7 (1.9) 9 (2.3) 4 (2.2) 
Headache 26 (7.0) 34 (8.6)† 12 (6.5) 
Cough 8 (2.1) 11 (2.8) 4 (2.2) 
Acne 8 (2.1)† 2 (0.5) 0 
Alopecia 10 (2.7) 8 (2.0) 5 (2.7) 
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Preferred Term Patients with Adverse Event, n (%) 
 Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Rash 3 (0.8) 12 (3.0)† 3 (1.6) 
Hypertension 26 (7.0)† 29 (7.3)† 7 (3.8) 
†Event occurred more frequently in patients receiving tofacitinib 5 or 10 mg twice daily compared with methotrexate; ‡event occurred more frequently in patients receiving 
methotrexate compared with tofacitinib 5 or 10 mg twice daily; based on risk difference (percent of patients with an adverse event for tofacitinib minus that for methotrexate) of >1 
or <-1; not adjusted for multiplicity and is for estimation purposes only. 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
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Table S5. Serious Adverse Events Over 24 Months (1 Patient per Term Unless Indicated Otherwise). 
MedDRA System Organ Class Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
    
    
Blood and lymphatic system disorders  Disseminated intravascular 
coagulation 
 
Cardiac disorders Angina pectoris (2 patients), 
unstable angina, myocardial 
ischemia, cardiac failure 
Cardiac failure congestive, 
myocardial ischemia 
Atrial flutter, atrial fibrillation, 
atrioventricular block first 
degree 
Eye disorders Cataract (2 patients), scleritis   
Gastrointestinal disorders Abdominal hernia, abdominal 
wall hematoma, gastric ulcer, 
esophageal ulcer, enterocolitis, 
gastroenteritis, gastric ulcer 
perforation 
Abdominal pain, colonic stenosis, 
diarrhea, gastritis, constipation, 
pancreatitis, salivary gland 
calculus 
Hemorrhoids, salivary gland 
calculus, pancreatitis, inguinal 
hernia 
General disorders and administration 
site conditions 
Chest pain, lumbar hernia, 
pyrexia 
Noncardiac chest pain, chest pain  
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MedDRA System Organ Class Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Hepatobiliary disorders  Cholecystitis acute, biliary colic 
hepatomegaly 
Cholelithiasis 
Immune system disorders Hypersensitivity   
Infections and infestations Pneumonia (2 patients), herpes 
zoster, dengue fever, 
gastrointestinal infection, pleural 
infection, subcutaneous abscess, 
tonsillitis bacterial, sepsis, 
erysipelas 
Pneumonia, herpes zoster, herpes 
zoster disseminated, 
gastroenteritis (2 patients), bone 
tuberculosis, pyelonephritis 
chronic, diverticulitis, lower 
respiratory tract infection 
Nasopharyngitis, gastroenteritis, 
sialoadenitis, chronic hepatitis 
C, varicella 
Injury, poisoning and procedural 
complications 
Humerus fracture, fracture, 
tendon rupture, patella fracture 
Joint dislocation, wrist fracture, 
upper limb fracture, compression 
fracture, humerus fracture, ankle 
fracture, gunshot wound 
Ankle fracture, femoral neck 
fracture, fall, humerus fracture 
Musculoskeletal and connective tissue 
disorders 
Muscle hemorrhage, 
osteonecrosis, rheumatoid 
arthritis 
Arthralgia, osteoarthritis (3 
patients), pathological fracture, 
spinal column stenosis 
Intervertebral disc protrusion, 
musculoskeletal chest pain, 
rheumatoid arthritis, arthralgia 
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MedDRA System Organ Class Tofacitinib 5 mg Twice Daily 
(N=373) 
Tofacitinib 10 mg Twice Daily  
(N=397) 
Methotrexate 
(N=186) 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Non-Hodgkin lymphoma, T-cell 
cytolytic leukemia 
Burkitt-like lymphoma, prostate 
cancer, colon cancer 
Gastric cancer 
Nervous system disorders Carotid artery stenosis, 
cerebrovascular accident 
 
Cerebrovascular accident (2 
patients), demyelinating 
polyneuropathy, nervous system 
disorder 
 
Psychiatric disorders  Psychotic disorder Psychotic disorder 
Renal and urinary disorders Calculus urinary Hydronephrosis, ureteric stenosis Urinary tract disorder 
Reproductive system and breast 
disorders 
Ovarian cyst Uterine polyp, endometrial 
hyperplasia (2 patients) 
Metrorrhagia 
Respiratory, thoracic and mediastinal 
disorders 
 Bronchitis chronic, chronic 
obstructive pulmonary disease (2 
patients) 
 
Skin and subcutaneous tissue disorders Erythema annulare  Erythema multiforme 
Vascular disorders Deep vein thrombosis Rheumatoid vasculitis Deep vein thrombosis (2 
patients) 
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MedDRA, Medical Dictionary for Regulatory Activities 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week 
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Table S6. Further Details on Laboratory Data at Months 6, 12, and 24. 
 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Mean change from baseline# 
Absolute neutrophil count, 
103/mm3 (SE) 
-1.18* 
(0.09) 
-1.42** 
(0.09) 
-0.83  
(0.13) 
-1.17  
(0.09) 
-1.50**  
(0.09) 
-0.97  
(0.14) 
-1.26 
(0.10) 
-1.61 
(0.09) 
-1.03  
(0.15) 
Absolute lymphocyte count, 
103/mm3 (95% CI) 
0.03** 
(-0.03, 0.09) 
0.04** 
(-0.02, 0.10) 
-0.15 
(-0.24, -0.06) 
-0.11 
(-0.17, -0.04) 
-0.18 
(-0.24, -0.12) 
-0.13 
(-0.22, -0.03) 
-0.35* 
(-0.41, -0.28) 
-0.44** 
(-0.51, -0.38) 
-0.22 
 (-0.32, -0.11) 
Hemoglobin, g/dL (SD)‡ 0.49 (1.11) 0.32 (1.07) 0.16 (1.02) 0.47 (1.19) 0.31 (1.05) 0.26 (1.11) 0.57 (1.26) 0.24 (1.12) 0.30 (1.15) 
LDL-c, mg/dL, % change 
(SE) 
14.47** 
(1.54) 
19.51** 
(1.48) 
2.12 
 (2.18) 
16.77**  
(1.58) 
22.05**  
(1.52) 
2.24  
(2.29) 
18.57**  
(1.65) 
21.63**  
(1.59) 
3.91  
(2.47) 
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
HDL-c, mg/dL, % change 
(SE) 
20.70** 
(1.41) 
20.76** 
(1.35) 
6.89  
(2.00) 
18.68**  
(1.43) 
19.15** 
 (1.38) 
2.96  
(2.08) 
16.79** 
(1.49) 
17.38** 
(1.43) 
6.98 
(2.21) 
Serum creatinine, mg/dL 
(SE) 
0.08** 
(0.01) 
0.09** 
(0.01) 
0.03  
(0.01) 
0.09** 
(0.01) 
0.09**  
(0.01) 
0.04  
(0.01) 
0.10** 
(0.01) 
0.10** 
(0.01) 
0.04  
(0.01) 
Incidence, n (%)    
Neutropenia (SE)          
ANC ≥1.5 to <2 × 
103/μL 
6 (1.8) 10 (2.7) 4 (2.5) 6 (1.9) 16 (4.9) 1 (<1.0) 9 (3.5) 12 (4.3) 1 (<1.0) 
ANC ≥0.5 to <1.5 × 
103/μL 
3 (<1.0) 4 (1.1) 0 3 (<1.0) 1 (<1.0) 0 1 (<1.0) 5 (1.8) 0 
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
ANC <0.5 × 103/μL 0 0 0 0 0 0 0 0 0 
Lymphopenia          
1.5 - ≤2.0 × 109/L 
lymphocytes 
116 (34.2) 112 (30.9) 62 (39.2) 109 (35.2) 101 (30.8) 47 (36.2) 82 (32.0) 71 (25.5) 36 (35.3) 
0.5 - <1.5 × 109/L 
lymphocytes 
85 (25.1) 93 (25.6) 51 (32.3) 100 (32.3) 127 (38.7) 43 (33.1) 116 (45.3) 158 (56.8) 36 (35.3) 
<0.5 × 109/L 
lymphocytes 
0 2 (<1.0) 0 0 0 0 1 (<1.0) 1 (<1.0) 0 
Decreased hemoglobin          
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Decrease of ≥1 g/dL to 
≤2 g/dL versus baseline 
23 (6.8) 25 (6.8) 18 (11.4) 26 (8.4) 31 (9.8) 16 (12.2) 18 (7.0) 27 (9.7) 5 (4.9) 
Decrease of >2 g/dL to 
<3 g/dL versus baseline 
or an actual hemoglobin 
value of >7 g/dL, but 
<8 g/dL 
2 (<1.0) 4 (1.1) 1 (<1.0) 3 (<1.0) 0 2 (1.5) 2 (<1.0) 3 (1.1) 3 (2.9) 
Decrease of ≥3 g/dL 
versus baseline or an 
actual hemoglobin value 
of ≤7 g/dL 
0 0 1 (<1.0) 1 (<1.0) 0 0 0 0 1 (<1.0) 
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 Month 6 Month 12 Month 24 
 Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg 
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
Tofacitinib 
5 mg  
Twice Daily 
(N=373) 
Tofacitinib 
10 mg 
Twice Daily  
(N=397) 
Methotrexate  
 
 
(N=186) 
LDL-c <100 mg/dL at 
baseline and ≥130 mg/dL 
over Months 0–24 
      41 (11.0) 47 (11.8) 5 (2.7) 
 
‡No comparison of tofacitinib versus methotrexate available; #Least squares means from analysis of covariance or mixed-effect longitudinal model; 
ANC, absolute neutrophil count; CI, confidence interval; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SD, standard deviation; 
SE, standard error 
Mean methotrexate dose at end of titration (Month 3) = 18.5 mg/week  
*P≤0.05; **P<0.001 versus methotrexate 
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Table S7. Hepatic Aminotransferases and Increase in Serum Creatinine Data from Months 0 to 24.† 
 Tofacitinib 5 mg Twice Daily Tofacitinib 10 mg Twice Daily Methotrexate 
 (N=373) (N=397) (N=186) 
AST ≥1 × ULN 121 (32.9) 143 (36.1) 56 (30.4) 
AST ≥3 × ULN 6 (1.6) 6 (1.5) 6 (3.3) 
ALT ≥1 × ULN 132 (35.9) 150 (37.9) 79 (42.9) 
ALT ≥3 × ULN 11 (3.0) 12 (3.0) 13 (7.1) 
Serum creatinine ≥33% increase 37 (9.9) 38 (9.6) 5 (2.7) 
Serum creatinine >50% increase 6 (1.6) 11 (2.8) 0 
 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal 
†Confirmed (by two consecutive tests) 
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